The EPS miss and widening net loss are concerning, but the 31% QoQ revenue growth and CMS NTAP catalyst provide a counterbalance. Monitor Q3 2026 for continued patient treatment momentum and cash burn rate; the NTAP designation in October could drive hospital adoption and revenue acceleration.
Price Chart
Executive Summary
Abeona reported Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ, with five patients treated. However, EPS of -$0.35 missed the consensus estimate of -$0.24 by 45.8%, and the net loss widened to -$20.2M from -$17.1M in Q1, driven by a $7.2M non-cash warrant liability charge. The CMS NTAP designation for ZEVASKYN effective October 2026 is a positive catalyst, but the EPS miss and ongoing cash burn temper the outlook.
Key Financial Metrics
Key Facts
- Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ from $8.7M in Q1 2026.
- Five patients treated with ZEVASKYN in Q2; revenue recognized for four due to one batch below threshold.
- EPS of -$0.35 missed consensus estimate of -$0.24 by 45.8%.
- Net loss widened to -$20.2M from -$17.1M in Q1, including a $7.2M non-cash warrant liability charge.
- Cash, equivalents, and investments at $146.8M as of June 30, 2026, down from $191.4M at year-end 2025.
- CMS NTAP designation for ZEVASKYN effective October 1, 2026, expected to support hospital adoption.
- QTC network expanded to seven sites; Cincinnati Children's activated in Q3 2026.
Financial Impact
Q2 revenue $11.4M vs consensus $12.2M; EPS -$0.35 vs consensus -$0.24; net loss -$20.2M
Risk Factors
- EPS miss of 45.8% vs consensus signals operational underperformance relative to expectations.
- Cash burn continues; cash declined $44.6M in H1 2026, raising potential dilution risk.
- Revenue recognition risk: one of five Q2 treatments did not meet batch release specifications, highlighting manufacturing yield uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344400 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $5.47 $5.57 | ▲ +1.83% | ▲ +1.01% | $5.03 (−8.14%) |
Aug 14, 2026 6w ago | Institutional Cluster | $5.94 $6.06 | ▲ +2.02% | ▲ +3.21% | $5.03 (−15.40%) |
Aug 13, 2026 7w ago | 8-K | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Aug 13, 2026 7w ago | Press Release | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Jul 9, 2026 12w ago | Insider Cluster | $6.98 $7.02 | ▲ +0.57% | ▲ +1.13% | $5.03 (−28.01%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▲ +1.24% | ▲ +3.47% | $5.03 (−11.06%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▼ −1.24% | ▼ −3.47% | $5.03 (+11.06%) |
Jun 12, 2026 16w ago | 8-K | $5.53 $5.77 | ▲ +4.34% | ▲ +3.67% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | 8-K | $5.53 $5.65 | ▲ +2.17% | ▲ +1.74% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | Insider Cluster | $5.36 $5.65 | ▼ −5.41% | ▼ −1.98% | $5.03 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access